Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Basking Ridge, Commack, Duarte, Harrison, Houston, New York, Rockville Centre, and Sleepy Hollow, United StatesSee the 8 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 18 people, planned
- Started
- Dec 2009
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age>18
- Karnofsky Performance Status (KPS) ≥ 70
- Newly diagnosed or recurrent thymoma - WHO A, AB, B1, B2, or B340, or thymic carcinoma pathologically confirmed at MSKCC, MDACC or City of Hope
- No prior chemotherapy, radiotherapy, or surgical therapy (other than for diagnostic biopsy) for thymoma
- No prior treatment with cetuximab
- Clinical Masaoka Stage II (>5cm), III, or IVA(See Appendix B), including suspected invasion of mediastinum, pericardium, lung, great vessels or chest wall, and/or pleural metastases Normal marrow function: leukocytes ≥ 4,000/μl, absolute neutrophil count ≥ 1,500/μl, platelets ≥ 160,000/μl
- Adequate renal function, with creatinine ≤ 1.3 mg/dl or calculated creatinine clearance ≥60ml/min by Cockcroft and Gault equation using parameters of age, weight (kg), and baseline serum creatinine (mg/dl)
- Adequate hepatic function: Total bilirubin ≤1.5 mg/dl, AST ≤1.5X UNL, alkaline phosphatase ≤1.5 UN
- Signed informed consent
- Effective contraception
- Medically operable
Who cannot take part
- Patients must not be receiving any other investigational agents
- Known HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with the study drugs. Patients on medications known to alter CYP3A4
- Evidence of distant metastatic disease (Masaoka stage IVB)
- Concurrent or prior malignancy in the last 5 years other than non-melanoma skin cancer and in-situ carcinoma of the cervix
- Thymic carcinoid
- Pregnant or breastfeeding women
Where in United States
- Memorial Sloan Kettering at Basking RidgeBasking Ridge, United States
- Memorial Sloan Kettering Cancer Center @ SuffolkCommack, United States
- City of Hope Medical CenterDuarte, United States
- Memorial Sloan Kettering West HarrisonHarrison, United States
- MD Anderson Cancer CenterHouston, United States
- Memorial Sloan-Kettering Cancer CenterNew York, United States
- Memorial Sloan Kettering at Mercy Medical CenterRockville Centre, United States
- Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital CenterSleepy Hollow, United States
About the trial
What the trial wants to find out
The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thymoma or thymic carcinoma before surgery. The physicians will also look at changes in genes in the tumor that may relate to the effectiveness of cetuximab
The group in the trial
- Cetuximab, Cisplatin, Doxorubicin & CyclophosphamideTreatment being tested
This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)
- Record updated
- 29 July 2026